Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery

Journal of Photochemistry and Photobiology C: Photochemistry Reviews

Volumn 23, Issue , 2015, Pages 103-131

  Weijer, Ruud ^a   Broekgaarden, Mans ^a   Kos, Milan ^a   van Vught, Remko ^b   Rauws, Erik A J ^c   Breukink, Eefjan ^b   van Gulik, Thomas M ^a   Storm, Gert ^d,e   Heger, Michal ^a,b,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Cancer; Drug delivery; Metallated phthalocyanines; Photodynamic therapy; Photosensitizers; Reactive oxygen species; Singlet oxygen; Tumor targeting

Indexed keywords

CELL DEATH; CELLS; CYTOLOGY; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; LIPOSOMES; NITROGEN COMPOUNDS; PHOTODYNAMIC THERAPY; REFRACTORY MATERIALS; TUMORS;

CANCER; METALLATED PHTHALOCYANINES; REACTIVE OXYGEN SPECIES; SINGLET OXYGEN; TUMOR TARGETING;

PHOTOSENSITIZERS;

EID: 84938826215     PISSN: 13895567     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotochemrev.2015.05.002     Document Type: Review

References (387)

1. Plaetzer K., Krammer B., Berlanda J., Berr F., Kiesslich T. Photophysics and photochemistry of photodynamic therapy: fundamental aspects. Lasers Med. Sci. 2009, 24:259-268.
2. van Golen R.F., van Gulik T.M., Heger M. Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. Free Rad. Biol. Med. 2012, 52:1382-1402.
3. Henderson B.W., Dougherty T.J. How does photodynamic therapy work?. Photochem. Photobiol. 1992, 55:145-157.
4. Triesscheijn M., Baas P., Schellens J.H., Stewart F.A. Photodynamic therapy in oncology. Oncologist 2006, 11:1034-1044.
5. Benson R.C. Jr., Laser photodynamic therapy for bladder cancer. Mayo Clin. Proc. 1986, 61:859-864.
6. Copper M.P., Tan I.B., Oppelaar H., Ruevekamp M.C., Stewart F.A. Meta-tetra(hydroxyphenyl) chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2003, 129:709-711.
7. Dougherty T.J. Photodynamic therapy (PDT) of malignant tumors. Crit. Rev. Oncol. Hematol. 1984, 2:83-116.
8. Kubler A.C., de C.J., Hopper C., Leonard A.G., Putnam G. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int. J. Oral Maxillofac. Surg. 2001, 30:504-509.
9. Mackenzie G.D., Dunn J.M., Selvasekar C.R., Mosse C.A., Thorpe S.M., Novelli M.R., Bown S.G., Lovat L.B. Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med. Sci. 2009, 24:729-734.
10. Morales A. Treatment of superficial bladder cancer. Can. Med. Assoc. J. 1980, 122:1133-1138.
11. Morton C.A., Whitehurst C., Moseley H., McColl J.H., Moore J.V., Mackie R.M. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br. J. Dermatol. 1996, 135:766-771.
12. Rosenberg S.J., Williams R.D. Photodynamic therapy of bladder carcinoma. Urol. Clin. North Am. 1986, 13:435-444.
13. Sibille A., Lambert R., Souquet J.C., Sabben G., Descos F. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995, 108:337-344.
14. Zeitouni N.C., Shieh S., Oseroff A.R. Laser and photodynamic therapy in the management of cutaneous malignancies. Clin. Dermatol. 2001, 19:328-338.
15. Nseyo U.O., Shumaker B., Klein E.A., Sutherland K. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. J. Urol. 1998, 160:39-44.
16. Sun Z.Q. Photodynamic therapy of nasopharyngeal carcinoma by argon or dye laser-an analysis of 137 cases. Zhonghua Zhong Liu Za Zhi 1992, 14:290-292.
17. Dumoulin F.L., Gerhardt T., Fuchs S., Scheurlen C., Neubrand M., Layer G., Sauerbruch T. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest. Endosc. 2003, 57:860-867.
18. Wiedmann M., Berr F., Schiefke I., Witzigmann H., Kohlhaw K., Mossner J., Caca K. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest. Endosc. 2004, 60:68-75.
19. Rauws E.A.J. Photodynamic therapy and Klatskin tumour: an overview. Scand. J. Gastroenterol. 2006, 41:135-138.
20. Oku N., Namba Y., Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim. Biophys. Acta 1992, 1126:255-260.
21. R.T. van Kooten, W. Perini, L.G. Dijkstra, S.R. Veldkamp, A.K. Warps, E. van Elsäcker, M. Hafdi, Q. Hofsink, M. Kos, M. Broekgaarden, R. Weijer, R. van Vught, S. Oliveira, Y. Liu, Y. Nie, Z. Gu, J. Birkhoff, I.B. Tan, G. Storm, M. Heger, Lipid-based nanoparticulate drug delivery systems for photodynamic therapy of solid cancers: the utility of photosensitizer encapsulation. Manuscript in preparation (2015).
22. Allison R.R., Downie G.H., Cuenca R., Hu X.H., Childs C.J., Sibata C.H. Photosensitizers in clinical PDT. Photodiagn. Photodyn. Ther. 2004, 1:27-42.
23. Wooten R.S., Smith K.C., Ahlquist D.A., Muller S.A., Balm R.K. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg. Med. 1988, 8:294-300.
24. Oseroff A.R., Blumenson L.R., Wilson B.D., Mang T.S., Bellnier D.A., Parsons J.C., Frawley N., Cooper M., Zeitouni N., Dougherty T.J. A dose ranging study, of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg. Med. 2006, 38:417-426.
25. Regula J., MacRobert A.J., Gorchein A., Buonaccorsi G.A., Thorpe S.M., Spencer G.M., Hatfield A.R.W., Bown S.G. Photosensitization and photodynamic therapy of esophageal, duodenal, and colorectal tumors using 5-aminolevulinic acid-induced protoporphyrin-IX-a pilot-study. Gut 1995, 36:67-75.
26. Wagnieres G., Hadjur C., Grosjean P., Braichotte D., Savary J.F., Monnier P., van den Bergh H. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl) chlorin. Photochem. Photobiol. 1998, 68:382-387.
27. Peng Q., Nesland J.M., Moan J., Evensen J.F., Kongshaug M., Rimington C. Localization of fluorescent Photofrin-II and aluminum phthalocyanine tetrasulfonate in transplanted human malignant tumor LOX and normal tissues of nude mice using highly light-sensitive video intensification microscopy. Int. J. Cancer 1990, 45:972-979.
28. Boyle D.G., Potter W.R. Photobleaching of Photofrin II as a means of eliminating skin photosensitivity. Photochem. Photobiol. 1987, 46:997-1001.
29. Jacques S.L. How tissue optics affect dosimetry of photodynamic therapy. J. Biomed. Opt. 2010, 15:51608.
30. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41:189-207.
31. Bellnier D.A., Ho Y.K., Pandey R.K., Missert J.R., Dougherty T.J. Distribution and elimination of Photofrin II in mice. Photochem. Photobiol. 1989, 50:221-228.
32. Gomer C.J., Ferrario A. Tissue distribution and photosensitizing properties of mono-l-aspartyl chlorin e6 in a mouse tumor model. Cancer Res. 1990, 50:3985-3990.
33. Chan W.S., Marshall J.F., Svensen R., Bedwell J., Hart I.R. Effect of sulfonation on the cell and tissue distribution of the photosensitizer aluminum phthalocyanine. Cancer Res. 1990, 50:4533-4538.
34. Van de Putte M., Roskams T., Bormans G., Verbruggen A., de Witte P.A.M. The impact of aggregation on the biodistribution of hypericin. Int. J. Oncol. 2006, 28:655-660.
35. Barel A., Jori G., Perin A., Romandini P., Pagnan A., Biffanti S. Role of high-density, low-density and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. Cancer Lett. 1986, 32:145-150.
36. Elfar M.A., Pimstone N.R. Tumor-localization of uroporphyrin isomer-I and isomer-III and their correlation to albumin and serum-protein binding. Cell Biochem. Funct. 1983, 1:156-160.
37. Freitas I. Lipid accumulation: the common feature to photosensitizer-retaining normal and malignant tissues. J. Photochem. Photobiol. B 1990, 7:359-361.
38. Bugelski P.J., Porter C.W., Dougherty T.J. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res. 1981, 41:4606-4612.
39. Peng Q., Moan J., Cheng L.S. The effect of glucose administration on the uptake of Photofrin-II in a human tumor xenograft. Cancer Lett. 1991, 58:29-35.
40. Korbelik M., Krosl G., Olive P.L., Chaplin D.J. Distribution of Photofrin between tumor cells and tumor-associated macrophages. Br. J. Cancer 1991, 64:508-512.
41. Jori G. In vivo transport and pharmacokinetic behavior of tumour photosensitizers. Ciba Found. Symp. 1989, 146:78-86.
42. Chopp M., Dereski M.O., Madigan L., Jiang F., Logie B. Sensitivity of 9L gliosarcomas to photodynamic therapy. Radiat. Res. 1996, 146:461-465.
43. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr. 2006, 16:279-305.
44. Gatter K.C., Brown G., Trowbridge I.S., Woolston R.E., Mason D.Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 1983, 36:539-545.
45. Vitols S., Gahrton G., Ost A., Peterson C. Elevated low-density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 1984, 63:1186-1193.
46. Stehle G., Sinn H., Wunder A., Schrenk H.H., Stewart J.C.M., Hartung G., MaierBorst W., Heene D.L. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol. 1997, 26:77-100.
47. Nakajima S., Takemura T., Sakata I. Tumor-localizing activity of porphyrin and its affinity to LDL, transferrin. Cancer Lett. 1995, 92:113-118.
48. Kessel D. Porphyrin-lipoprotein association as a factor in porphyrin localization. Cancer Lett. 1986, 33:183-188.
49. Ginevra F., Biffanti S., Pagnan A., Biolo R., Reddi E., Jori G. Delivery of the tumor photosensitizer zinc(II)-phthalocyanine to serum proteins by different liposomes-studies in vitro and in vivo. Cancer Lett. 1990, 49:59-65.
50. Alarcon E., Edwards A.M., Garcia A.M., Munoz M., Aspee A., Borsarelli C.D., Lissi E.A. Photophysics and photochemistry of zinc phthalocyanine/bovine serum albumin adducts. Photochem. Photobiol. Sci. 2009, 8:255-263.
51. Mojzisova H., Bonneau S., Vever-Bizet C., Brault D. Cellular uptake and subcellular distribution of chlorin e6 as functions of pH and interactions with membranes and lipoproteins. Biochim. Biophys. Acta 2007, 1768:2748-2756.
52. Woodburn K.W., Vardaxis N.J., Hill J.S., Kaye A.H., Phillips D.R. Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem. Photobiol. 1991, 54:725-732.
53. Chen L.B. Mitochondrial-membrane potential in living cells. Ann. Rev. Cell Biol. 1988, 4:155-181.
54. Lin C.W., Shulok J.R., Kirley S.D., Cincotta L., Foley J.W. Lysosomal localization and mechanism of uptake of Nile Blue photosensitizers in tumor cells. Cancer Res. 1991, 51:2710-2719.
55. Wessels J.M., Strauss W., Seidlitz H.K., Ruck A., Schneckenburger H. Intracellular localization of meso-tetraphenylporphine tetrasulfonate probed by time-resolved and microscopic fluorescence spectroscopy. J. Photochem. Photobiol. B 1992, 12:275-284.
56. J. Moan, K. Berg, S. H.B., W. T., M. K., Fluorescence and photodynamic effects of phthalocyanines and porphyrins in cells, in: B.W. Henderson, T.J. Dougherty (Eds.), Photodynamic Therapy. Basic Principles and Clinical Applications, Marcel-Dekker, New York, 1992, pp. 19-36.
57. Wilson B.C., Olivo M., Singh G. Subcellular localization of Photofrin(R) and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to Photofrin-mediated photodynamic therapy. Photochem. Photobiol. 1997, 65:166-176.
58. Shulok J.R., Wade M.H., Lin C.W. Subcellular localization of hematoporphyrin derivative in bladder tumor cells in culture. Photochem. Photobiol. 1990, 51:451-457.
59. Hsieh Y.J., Wu C.C., Chang C.J., Yu J.S. Subcellular localization of Photofrin(R) determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: when plasma membranes are the main targets. J. Cell. Physiol. 2003, 194:363-375.
60. Teiten M.H., Bezdetnaya L., Morliere P., Santus R., Guillemin F. Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan((R)) localisation in cultured tumour cells. Br. J. Cancer 2003, 88:146-152.
61. Fabris C., Valduga G., Miotto G., Borsetto L., Jori G., Garbisa S., Reddi E. Photosensitization with zinc(II) phthalocyanine as a switch in the decision between apoptosis and necrosis. Cancer Res. 2001, 61:7495-7500.
62. Ris H.B., Altermatt H.J., Nachbur B., Stewart J.C.M., Wang Q., Lim C.K., Bonnett R., Althaus U. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int. J. Cancer 1993, 53:141-146.
63. Sharman W.M., Allen C.M., van Lier J.E. Role of activated oxygen species in photodynamic therapy. Methods Enzymol. 2000, 319:376-400.
64. Weishaupt K.R., Gomer C.J., Dougherty T.J. Identification of singlet oxygen as cytotoxic agent in photo-inactivation of a murine tumor. Cancer Res. 1976, 36:2326-2329.
65. Redmond R.W., Kochevar I.E. Spatially resolved cellular responses to singlet oxygen. Photochem. Photobiol. 2006, 82:1178-1186.
66. M. Broekgaarden, R. Weijer, A.C. van Wijk, R.C. Cox, M.R. Egmond, R. Hoebe, T.M. van Gulik, M. Heger, Photodynamic therapy with liposomal zinc phtalocyanine and tirapazamine increases tumor cell death via DNA damage. Manuscript submitted, 2015.
67. Tada-Oikawa S., Oikawa S., Hirayama J., Hirakawa K., Kawanishi S. DNA damage and apoptosis induced by photosensitization of 5,10,15,20-tetrakis(N-methyl-4-pyridyl)-21H,23H-porphyrin via singlet oxygen generation. Photochem. Photobiol. 2009, 85:1391-1399.
68. Broekgaarden M., Weijer R., van Gulik T.M., Hamblin M.R., Heger M. Tumor cell survival pathways activated by photodynamic therapy: a molecular framework for inhibition strategies. Cancer Metastasis Rev. 2015, (in press).
69. Huang Z., Xu H.P., Meyers A.D., Musani A.I., Wang L.W., Tagg R., Barqawi A.B., Chen Y.K. Photodynamic therapy for treatment of solid tumors-potential and technical challenges. Technol. Cancer Res. Treat. 2008, 7:309-320.
70. Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 2004, 1:279-293.
71. Girotti A.W. Photodynamic lipid peroxidation in biological systems. Photochem. Photobiol. 1990, 51:497-509.
72. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Rad. Biol. Med. 2009, 47:469-484.
73. Tyrode E., Niga P., Johnson M., Rutland M.W. Molecular structure upon compression and stability toward oxidation of Langmuir films of unsaturated fatty acids: a vibrational sum frequency spectroscopy study. Langmuir 2010, 26:14024-14031.
74. Broekgaarden M., de Kroon A.I., van Gulik T.M., Heger M. Development and in vitro proof-of-concept of interstitially targeted zinc-phthalocyanine liposomes for photodynamic therapy. Curr. Med. Chem. 2013, 21:377-391.
75. Berg K., Madslien K., Bommer J.C., Oftebro R., Winkelman J.W., Moan J. Light-induced relocalization of sulfonated meso-tetraphenylporphines in Nhik 3025 cells and effects of dose fractionation. Photochem. Photobiol. 1991, 53:203-210.
76. Moan J., Berg K., Anholt H., Madslien K. Sulfonated aluminum phthalocyanines as sensitizers for photochemotherapy-effects of small light doses on localization, dye fluorescence and photosensitivity in V79 cells. Int. J. Cancer 1994, 58:865-870.
77. Wilson P.D., Firestone R.A., Lenard J. The role of lysosomal enzymes in killing of mammalian cells by the lysosomotropic detergent N-dodecylimidazole. J. Cell Biol. 1987, 104:1223-1229.
78. Kessel D., Conley M., Vicente M.G.H., Reiners J.J. Studies on the subcellular localization of the porphycene CPO. Photochem. Photobiol. 2005, 81:569-572.
79. Buytaert E., Callewaert G., Hendrickx N., Scorrano L., Hartmann D., Missiaen L., Vandenheede J.R., Heirman I., Grooten J., Agostinis P. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J. 2006, 20:756-758.
80. Moserova I., Kralova J. Role of ER stress response in photodynamic therapy: ROS generated in different subcellular compartments trigger diverse cell death pathways. Plos One 2012, 7. e32972.
81. Timmins J.M., Ozcan L., Seimon T.A., Li G., Malagelada C., Backs J., Backs T., Bassel-Duby R., Olson E.N., Anderson M.E., Tabas I. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J. Clin. Invest. 2009, 119:2925-2941.
82. Lemasters J.J., Nieminen A.L., Qian T., Trost L.C., Elmore S.P., Nishimura Y., Crowe R.A., Cascio W.E., Bradham C.A., Brenner D.A., Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta 1998, 1366:177-196.
83. Kessel D., Luo Y., Deng Y.Q., Chang C.K. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem. Photobiol. 1997, 65:422-426.
84. Kessel D., Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J. Photochem. Photobiol. B 1998, 42:89-95.
85. Chatterjee S.R., Possel H., Srivastava T.S., Kamat J.P., Wolf G., Devasagayam T.P.A. Photodynamic effects induced by meso-tetrakis[4-(carboxymethyleneoxy)phenyl]porphyrin on isolated Sarcoma 180 ascites mitochondria. J. Photochem. Photobiol. B 1999, 50:79-87.
86. Chatterjee S.R., Srivastava T.S., Kamat J.P., Devasagayam T.P.A. Lipid peroxidation induced by a novel porphyrin plus light in isolated mitochondria: possible implications in photodynamic therapy. Mol. Cell. Biochem. 1997, 166:25-33.
87. Plaetzer K., Kiesslich T., Krammer B., Hammerl P. Characterization of the cell death modes and the associated changes in cellular energy supply in response to AlPcS4-PDT. Photochem. Photobiol. Sci. 2002, 1:172-177.
88. Soldani C., Bottone M.G., Croce A.C., Fraschini A., Bottiroli G., Pellicciari C. The Golgi apparatus is a primary site of intracellular damage after photosensitization with Rose Bengal acetate. Eur. J. Histochem. 2004, 48:443-448.
89. Mukherjee S., Chiu R., Leung S.M., Shields D. Fragmentation of the Golgi apparatus: an early apoptotic event independent of the cytoskeleton. Traffic 2007, 8:369-378.
90. Chin R., Novikov L., Mukherjee S., Shields D. A caspase cleavage fragment of p115 induces fragmentation of the Golgi apparatus and apoptosis. J. Cell Biol. 2002, 159:637-648.
91. Ogata M., Inanami O., Nakajima M., Nakajima T., Hiraoka W., Kuwabara M. Ca(2+)-dependent and caspase-3-independent apoptosis caused by damage in golgi apparatus due to 2,4,5,7-tetrabromorhodamine 123 bromide-induced photodynamic effects. Photochem. Photobiol. 2003, 78:241-247.
92. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011, 61:250-281.
93. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998, 90:889-905.
94. Korbelik M. Induction of tumor immunity by photodynamic therapy. J. Clin. Laser Med. Surg. 1996, 14:329-334.
95. Korbelik M., Krosl G., Krosl J., Dougherty G.J. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 1996, 56:5647-5652.
96. Castano A.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6:535-545.
97. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nature Rev. Immunol. 2010, 10:826-837.
98. Gallo P.M., Gallucci S. The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 2013, 4:138.
99. Garg A.D., Nowis D., Golab J., Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010, 15:1050-1071.
100. Garg A.D., Nowis D., Golab J., Vandenabeele P., Krysko D.V., Agostinis P. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim. Biophys. Acta 2010, 1805:53-71.
101. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem. Photobiol. Sci. 2011, 10:670-680.
102. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2002, 2:185-194.
103. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
104. Korbelik M. Complement upregulation in photodynamic therapy-treated tumors: role of toll-like receptor pathway and NF kappa B. Cancer Lett. 2009, 281:232-238.
105. Stott B., Korbelik M. Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol. Immunother. 2007, 56:649-658.
106. Theriault J.R., Adachi H., Calderwood S.K. Role of scavenger receptors in the binding and internalization of heat shock protein 70. J. Immunol. 2006, 177:8604-8611.
107. Beg A.A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 2002, 23:509-512.
108. Fischer N., Haug M., Kwok W.W., Kalbacher H., Wernet D., Dannecker G.E., Holzer U. Involvement of CD91 and scavenger receptors in Hsp70-facilitated activation of human antigen-specific CD4(+) memory T cells. Eur. J. Immunol. 2010, 40:986-997.
109. Garg A.D., Krysko D.V., Verfaillie T., Kaczmarek A., Ferreira G.B., Marysael T., Rubio N., Firczuk M., Mathieu C., Roebroek A.J.M., Annaert W., Golab J., de Witte P., Vandenabeele P., Agostinis P. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012, 31:1062-1079.
110. Pawaria S., Binder R.J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat. Commun. 2011, 2:521.
111. Korbelik M., Sun J.H., Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res. 2005, 65:1018-1026.
112. Zhou F.F., Xing D., Chen W.R. Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells. Int. J. Cancer 2009, 125:1380-1389.
113. Etminan N., Peters C., Lakbir D., Bunemann E., Borger V., Sabel M.C., Hanggi D., Steiger H.J., Stummer W., Sorg R.V. Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. Br. J. Cancer 2011, 105:961-969.
114. Mitra S., Giesselman B.R., De Jesus-Andino F.J., Foster T.H. Tumor response to mTHPC-mediated photodynamic therapy exhibits strong correlation with extracellular release of HSP70. Lasers Surg. Med. 2011, 43:632-643.
115. Panzarini E., Inguscio V., Dini L. Immunogenic cell death: can it be exploited in photodynamic therapy for cancer?. Biomed. Res. Int. 2013, 482160.
116. Tracy E.C., Bowman M.J., Henderson B.W., Baumann H. Interleukin-1 alpha is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. Br. J. Cancer 2012, 107:1534-1546.
117. Krause K.H., Michalak M. Calreticulin. Cell 1997, 88:439-443.
118. Ostwald T.J., MacLennan D.H. Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J. Biol. Chem. 1974, 249:974-979.
119. Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., Bratton D.L., Oldenborg P.A., Michalak M., Henson P.M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334.
120. Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 2012, 12:860-875.
121. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., Metivier D., Larochette N., van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
122. Dudek A.M., Garg A.D., Krysko D.V., De Ruysscher D., Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev. 2013, 24:319-333.
123. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol. Immunother. 2012, 61:215-221.
124. Garg A.D., Dudek A.M., Ferreira G.B., Verfaillie T., Vandenabeele P., Krysko D.V., Mathieu C., Agostinis P. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013, 9:1292-1307.
125. Thomas J.O., Travers A.A. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 2001, 26:167-174.
126. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22:5551-5560.
127. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002, 3:995-1001.
128. Palumbo R., Sampaolesi M., De Marchis F., Tonlorenzi R., Colombetti S., Mondino A., Cossu G., Bianchi M.E. Extracellular HMGB1 a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 2004, 164:441-449.
129. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
130. Andersson U., Wang H.C., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Zhang M.H., Yang H., Tracey K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 2000, 192:565-570.
131. Chen G.Q., Ward M.F., Sama A.E., Wang H.C. Extracellular HMGB1 as a proinflammatory cytokine. J. Interferon Cytokine Res. 2004, 24:329-333.
132. Orlova V.V., Choi E.Y., Xie C.P., Chavakis E., Bierhaus A., Ihanus E., Ballantyne C.M., Gahmberg C.G., Bianchi M.E., Nawroth P.P., Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007, 26:1129-1139.
133. Yang D., Chen Q., Yang H., Tracey K.J., Bustin M., Oppenheim J.J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukocyte Biol. 2007, 81:59-66.
134. Bell C.W., Jiang W.W., Reich C.F., Pisetsky D.S. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 2006, 291:C1318-C1325.
135. Thorburn J., Horita H., Redzic J., Hansen K., Frankel A.E., Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2009, 16:175-183.
136. Bianchi M.E. HMGB1 loves company. J. Leukocyte Biol. 2009, 86:573-576.
137. Yang H., Antoine D.J., Andersson U., Tracey K.J. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J. Leukocyte Biol. 2013, 93:865-873.
138. Korbelik M., Zhang W., Merchant S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol. Immunother. 2011, 60:1431-1437.
139. Elliott M.R., Chekeni F.B., Trampont P.C., Lazarowski E.R., Kadl A., Walk S.F., Park D., Woodson R.I., Ostankovich M., Sharma P., Lysiak J.J., Harden T.K., Leitinger N., Ravichandran K.S. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461. 282-U165.
140. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y.T., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J.L., Schlemmer F., Tasdemir E., Uhl M., Genin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., Andre F., Lidereau R., McLaughlin N.M., Haynes N.M., Smyth M.J., Kroemer G., Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1171U1199.
141. Zitvogel L., Kepp O., Galluzzi L., Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 2012, 13:343-351.
142. Lang P.A., Merkler D., Funkner P., Shaabani N., Meryk A., Krings C., Barthuber C., Recher M., Bruck W., Haussinger D., Ohashi P.S., Lang K.S. Oxidized ATP inhibits T-cell-mediated autoimmunity. Eur. J. Immunol. 2010, 40:2401-2408.
143. Brackett C.M., Gollnick S.O. Photodynamic therapy enhancement of anti-tumor immunity. Photochem. Photobiol. Sci. 2011, 10:649-652.
144. Firczuk M., Nowis D., Golab J. PDT-induced inflammatory and host responses. Photochem. Photobiol. Sci. 2011, 10:653-663.
145. Mroz P., Hashmi J.T., Huang Y.Y., Lang N., Hamblin M.R. Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev. Clin. Immunol. 2011, 7:75-91.
146. Korbelik M. PDT-associated host response and its role in the therapy outcome. Lasers Surg. Med. 2006, 38:500-508.
147. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 2005, 23:975-1028.
148. Canti G., Lattuada D., Nicolin A., Taroni P., Valentini G., Cubeddu R. Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser-light. Anticancer Drugs 1994, 5:443-447.
149. Kabingu E., Vaughan L., Owczarczak B., Ramsey K.D., Gollnick S.O. CD8(+) T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4(+) T cells and dependent on natural killer cells. Br. J. Cancer 2007, 96:1839-1848.
150. Thong P.S.P., Ong K.W., Goh N.S.G., Kho K.W., Manivasager V., Bhuvaneswari R., Oliva M., Soo K.C. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007, 8:950-952.
151. Abdel-Hady E.S., Martin-Hirsch P., Duggan-Keen M., Stern P.L., Moore J.V., Corbitt G., Kitchener H.C., Hampson I.N. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001, 61:192-196.
152. Kabingu E., Oseroff A.R., Wilding G.E., Gollnick S.O. Enhanced systemic immune reactivity to a basal cell carcinoma associated antigen following photodynamic therapy. Clin. Cancer Res. 2009, 15:4460-4466.
153. Dragieva G., Hafner J., Dummer R., Schmid-Grendelmeier P., Roos M., Prinz B.M., Burg G., Binswanger U., Kempf W. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004, 77:115-121.
154. Szokalska A., Makowski M., Nowis D., Wilczynski G.M., Kujawa M., Wojcik C., Mlynarczuk-Bialy I., Salwa P., Bil J., Janowska S., Agostinis P., Verfaillie T., Bugajski M., Gietka J., Issat T., Glodkowska E., Mrowka P., Stoklosa T., Hamblin M.R., Mroz P., Jakobisiak M., Golab J. Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res. 2009, 69:4235-4243.
155. Debnath J., Baehrecke E.H., Kroemer G. Does autophagy contribute to cell death?. Autophagy 2005, 1:66-74.
156. Kessel D., Reiners J.J. Apoptosis and autophagy after mitochondrial or endoplasmic reticulum photodamage. Photochem. Photobiol. 2007, 83:1024-1028.
157. Kim H.R.C., Luo Y., Li G.Y., Kessel D. Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection. Cancer Res. 1999, 59:3429-3432.
158. Xue L.Y., Chiu S.M., Oleinick N.L. Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Oncogene 2001, 20:3420-3427.
159. Kessel D., Castelli M. Evidence that bcl-2 is the target of three photosensitizers that induce a rapid apoptotic response. Photochem. Photobiol. 2001, 74:318-322.
160. Liang X.H., Kleeman L.K., Jiang H.H., Gordon G., Goldman J.E., Berry G., Herman B., Levine B. Protection against fatal Sindbis virus encephalitis by Beclin, a novel Bcl-2-interacting protein. J. Virol. 1998, 72:8586-8596.
161. Pattingre S., Tassa A., Qu X.P., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
162. Kessel D., Arroyo A.S. Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem. Photobiol. Sci. 2007, 6:1290-1295.
163. Andrzejak M., Price M., Kessel D.H. Apoptotic and autophagic responses to photodynamic therapy in 1c1c7 murine hepatoma cells. Autophagy 2011, 7:979-984.
164. Boya P., Gonzalez-Polo R.A., Casares N., Perfettini J.L., Dessen P., Larochette N., Metivier D., Meley D., Souquere S., Yoshimori T., Pierron G., Codogno P., Kroemer G. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 2005, 25:1025-1040.
165. Yan C.H., Liang Z.Q., Gu Z.L., Yang Y.P., Reid P., Qin Z.H. Contributions of autophagic and apoptotic mechanisms to CrTX-induced death of K562 cells. Toxicon 2006, 47:521-530.
166. Allen C.M., Sharman W.M., Van Lier J.E. Current status of phthalocyanines in the photodynamic therapy of cancer. J. Porphyrins Phthalocyanines 2001, 5:161-169.
167. Brasseur N. Sensitizers for PDT: phthalocyanines. Photodynamic Therapy 2004, 107-114. Royal Society of Chemistry, Cambridge. T. Patrice (Ed.).
168. van Lier J.E., Spikes J.D. The chemistry, photophysics and photosensitizing properties of phthalocyanines. Ciba Found. Symp. 1989, 146:17-26.
169. Wagner J.R., Ali H., Langlois R., Brasseur N., Vanlier J.E. Biological activities of phthalocyanines VI. Photooxidation of l-tryptophan by selectively sulfonated gallium phthalocyanines-singlet oxygen yields and effect of aggregation. Photochem. Photobiol. 1987, 45:587-594.
170. Darwent J.R., Douglas P., Harriman A., Porter G., Richoux M.C. Metal phthalocyanines and porphyrins as photosensitizers for reduction of water to hydrogen. Coord. Chem. Rev. 1982, 44:83-126.
171. Ben-Hur E. Basic photobiology and mechanisms of action of phthalocyanines. Photodynamic Therapy, Basic Principles and Clinical Applications 1992, 63-77. Marcel Dekker, New York. T.J. Dougherty, B.W. Henderson (Eds.).
172. Ochsner M. Light scattering of human skin: a comparison between zinc(II)-phthalocyanine and Photofrin II. J. Photochem. Photobiol. B 1996, 32:3-9.
173. Baron E.D., Malbasa C.L., Santo-Domingo D., Fu P.F., Miller J.D., Hanneman K.K., Hsia A.H., Oleinick N.L., Colussi V.C., Cooper K.D. Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg. Med. 2010, 42:728-735.
174. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J. Photochem. Photobiol. B 1997, 39:1-18.
175. Bellnier D.A., Greco W.R., Loewen G.M., Nava H., Oseroff A.R., Dougherty T.J. Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (Photochlor) and 5-ALA-induced protoporphyrin IX. Lasers Surg. Med. 2006, 38:439-444.
176. Berlanda J., Kiesslich T., Engelhardt V., Krammer B., Plaetzer K. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J. Photochem. Photobiol. B 2010, 100:173-180.
177. Amin R.M., Hauser C., Kinzler I., Rueck A., Scalfi-Happ C. Evaluation of photodynamic treatment using aluminum phthalocyanine tetrasulfonate chloride as a photosensitizer: new approach. Photochem. Photobiol. Sci. 2012, 11:1156-1163.
178. Tapajos E.C.C., Longo J.P., Simioni A.R., Lacava Z.G.M., Santos M.F.M.A., Morais P.C., Tedesco A.C., Azevedo R.B. In vitro photodynamic therapy on human oral keratinocytes using chloroaluminum-phthalocyanine. Oral Oncol. 2008, 44:1073-1079.
179. Ben-Hur E., Fujihara T., Suzuki F., Elkind M.M. Genetic toxicology of the photosensitization of Chinese hamster cells by phthalocyanines. Photochem. Photobiol. 1987, 45:227-230.
180. Halkiotis K., Yova D., Pantelias G. In vitro evaluation of the genotoxic and clastogenic potential of photodynamic therapy. Mutagenesis 1999, 14:193-198.
181. Mcnair F.I., Marples B., West C.M.L., Moore J.V. A comet assay of DNA damage and repair in K562 cells after photodynamic therapy using haematoporphyrin derivative, methylene blue and meso-tetrahydroxyphenylchlorin. Br. J. Cancer 1997, 75:1721-1729.
182. Yow C.M.N., Mak N.K., Szeto S., Chen J.Y., Lee Y.L., Cheung N.H., Huang D.P., Leung A.W.N. Photocytotoxic and DNA damaging effect of Temoporfin (mTHPC) and merocyanine 540 (MC540) on nasopharyngeal carcinoma cell. Toxicol. Lett. 2000, 115:53-61.
183. Duez P., Hanocq M., Dubois J. Photodynamic DNA damage mediated by delta-aminolevulinic acid-induced porphyrins. Carcinogenesis 2001, 22:771-778.
184. Fiedler D.M., Eckl P.M., Krammer B. Does delta-aminolaevulinic acid induce genotoxic effects?. J. Photochem. Photobiol. B 1996, 33:39-44.
185. Bohr V.A., Stevnsner T., de Souza-Pinto N.C. Mitochondrial DNA repair of oxidative damage in mammalian cells. Gene 2002, 286:127-134.
186. Kiesslich T., Berlanda J., Plaetzer K., Krammer B., Berr F. Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan-(R) and Foslip (R)-based photodynamic treatment in human biliary tract cancer cell lines. Photochem. Photobiol. Sci. 2007, 6:619-627.
187. Leunig M., Richert C., Gamarra F., Lumper W., Vogel E., Jocham D., Goetz A.E. Tumor-localization kinetics of Photofrin and three synthetic prophyrinoids in an amelanotic melanoma of the hamster. Br. J. Cancer 1993, 68:225-234.
188. Iinuma S., Bachor R., Flotte T., Hasan T. Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model. J. Urol. 1995, 153:802-806.
189. Ronn A.M., Nouri M., Lofgren L.A., Steinberg B.M., Westerborn A., Windahl T., Shikowitz M.J., Abramson A.L. Human tissue levels and plasma pharmacokinetics of temoporfin (Foscan(R), mTHPC). Lasers Med. Sci. 1996, 11:267-272.
190. Reddi E., Locastro G., Biolo R., Jori G. Pharmacokinetic studies with zinc(II)-phthalocyanine in tumor-bearing mice. Br. J. Cancer 1987, 56:597-600.
191. Polo L., Segalla A., Jori G., Bocchiotti G., Verna G., Franceschini R., Mosca R., DeFilippi P.G. Liposome-delivered I-131-labelled Zn(II)-phthalocyanine as a radiodiagnostic agent for tumours. Cancer Lett. 1996, 109:57-61.
192. Peng Q., Moan J., Kongshaug M., Evensen J.F., Anholt H., Rimington C. Sensitizer for photodynamic therapy of cancer-a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. Int. J. Cancer 1991, 48:258-264.
193. Woodburn K.W., Fan Q., Miles D.R., Kessel D., Luo Y., Young S.W. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem. Photobiol. 1997, 65:410-415.
194. Chiou J.F., Wang Y.H., Jou M.J., Liu T.Z., Shiau C.Y. Verteporfin-photoinduced apoptosis in HepG2 cells mediated by reactive oxygen and nitrogen species intermediates. Free Rad. Res. 2010, 44:155-170.
195. Deshpande P.P., Biswas S., Torchilin V.P. Current trends in the use of liposomes for tumor targeting. Nanomedicine 2013, 8:1509-1528.
196. Lukyanov A., Gao Z., Mazzola L., Torchilin V. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm. Res. 2002, 19:1424-1429.
197. Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Gasco M.R. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000, 42:337-343.
198. Guo P., Song S., Li Z., Tian Y., Zheng J., Yang X., Pan W. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy. Int. J. Pharm. 2015, 486:356-366.
199. Kuo Y.-C., Shih-Huang C.-Y. Solid lipid nanoparticles with surface antibody for targeting the brain and inhibiting lymphatic phagocytosis. J. Taiwan Inst. Chem. Eng. 2014, 45:1154-1163.
200. Hamblin M.R., Newman E.L. Photosensitizer targeting in photodynamic therapy. II. Conjugates of haematoporphyrin with serum lipoproteins. J. Photochem. Photobiol. B 1994, 26:147-157.
201. Reddi E., Zhou C., Biolo R., Menegaldo E., Jori G. Liposome- or LDL-administered Zn(II)-phthalocyanine as a photodynamic agent for tumors I. Pharmacokinetic properties and phototherapeutic efficiency. Br. J. Cancer 1990, 61:407-411.
202. Harisa G.I., Alanazi F.K. Low density lipoprotein bionanoparticles: from cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm. J. 2014, 22:504-515.
203. Svenson S., Tomalia D.A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 2012, 64(Suppl):102-115.
204. Madaan K., Kumar S., Poonia N., Lather V., Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J. Pharm. Bioallied Sci. 2014, 6:139-150.
205. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-16.
206. Yokoyama M. Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. J. Exp. Clin. Med. 2011, 3:151-158.
207. Sibani S.A., McCarron P.A., Woolfson A.D., Donnelly R.F. Photosensitiser delivery for photodynamic therapy. Part 2: systemic carrier platforms. Expert Opin. Drug Deliv. 2008, 5:1241-1254.
208. Manoukian M.A., Ott S.V., Rajadas J., Inayathullah M. Polymeric nanoparticles to combat squamous cell carcinomas in patients with dystrophic epidermolysis bullosa. Recent Pat. Nanomed. 2014, 4:15-24.
209. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B 2010, 75:1-18.
210. Ricci-Júnior E., Marchetti J.M. Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. Int. J. Pharm. 2006, 310:187-195.
211. Shibu E.S., Hamada M., Murase N., Biju V. Nanomaterials formulations for photothermal and photodynamic therapy of cancer. J. Photochem. Photobiol. C. 2013, 15:53-72.
212. Gamaleia N.F., Shton I.O. Gold mining for PDT: Great expectations from tiny nanoparticles. Photodiagn. Photodyn. Ther. 2015, 10.1016/j.pdpdt.2015.03.002.
213. Khlebtsov B.N., Khanadeev V.A., Maksimova I.L., Terentyuk G.S., Khlebtsov N.G. Silver nanocubes and gold nanocages: Fabrication and optical and photothermal properties. Nanotechnol. Russ. 2010, 5:454-468.
214. Li L., Zhao J.F., Won N., Jin H., Kim S., Chen J.Y. Quantum dot-aluminum phthalocyanine conjugates perform photodynamic reactions to kill cancer cells via fluorescence resonance energy transfer. Nanoscale Res. Lett. 2012, 7:386.
215. Chang H.I., Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomed. 2012, 7:49-60.
216. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications existing and potential. Int. J. Nanomed. 2006, 1:297-315.
217. Aguilar G., Choi B., Broekgaarden M., Yang O.W., Yang B., Ghasri P., Chen J.K., Bezemer R., Nelson J.S., van Drooge A.M., Wolkerstorfer A., Kelly K.M., Heger M. An overview of three promising mechanical, optical, and biochemical engineering approaches to improve selective photothermolysis of refractory port wine stains. Ann. Biomed. Eng. 2012, 40:486-506.
218. Damoiseau X., Schuitmaker H.J., Lagerberg J.W.M., Hoebeke M. Increase of the photosensitizing efficiency of the bacteriochlorin a by liposome-incorporation. J. Photochem. Photobiol. B 2001, 60:50-60.
219. Dhami S., Phillips D. Comparison of the photophysics of an aggregating and non-aggregating aluminium phthalocyanine system incorporated into unilamellar vesicles. J. Photochem. Photobiol. A 1996, 100:77-84.
220. Garcia A.M., Alarcon E., Munoz M., Scaiano J.C., Edwards A.M., Lissi E. Photophysical behaviour and photodynamic activity of zinc phthalocyanines associated to liposomes. Photochem. Photobiol. Sci. 2011, 10:507-514.
221. Derycke A.S.L., de Witte P.A.M. Liposomes for photodynamic therapy. Adv. Drug Deliv. Rev. 2004, 56:17-30.
222. Jori G. Factors controlling the selectivity and efficiency of tumour damage in photodynamic therapy. Lasers Med. Sci. 1990, 5:115-120.
223. Campbell P.I. Toxicity of some charged lipids used in liposome preparations. Cytobios 1983, 37:21-26.
224. Mayhew E., Ito M., Lazo R. Toxicity of non-drug containing liposomes for cultured human cells. Exp. Cell Res. 1987, 171:195-202.
225. Banerjee R. Liposomes: applications in medicine. J. Biomater. Appl. 2001, 16:3-21.
226. Awasthi V.D., Garcia D., Goins B.A., Phillips W.T. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm. 2003, 253:121-132.
227. Allen T.M., Hansen C., Martin F., Redemann C., Yauyoung A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.
228. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-237.
229. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes-improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:11460-11464.
230. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction withp plasma protein and clearance from the circulation-studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
231. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface-on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994, 1195:11-20.
232. Needham D., Mcintosh T.J., Lasic D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta 1992, 1108:40-48.
233. Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1992, 1103:94-100.
234. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., Papahadjopoulos D. Sterically stabilized liposomes-a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1991, 1070:187-192.
235. Harding J.A., Engbers C.M., Newman M.S., Goldstein N.I., Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim. Biophys. Acta 1997, 1327:181-192.
236. Bovis M.J., Woodhams J.H., Loizidou M., Scheglmann D., Bown S.G., MacRobert A.J. Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy. J. Control. Release 2012, 157:196-205.
237. Buchholz J., Kaser-Hotz B., Khan T., Bleyl C.R., Melzer K., Schwendener R.A., Roos M., Walt H. Optimizing photodynamic therapy: in vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl) chlorin in feline squamous cell carcinoma. Clin. Cancer Res. 2005, 11:7538-7544.
238. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., Allen T.M. Attachment of antibodies to sterically stabilized liposomes-evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1995, 1239:133-144.
239. Shahinian S., Silvius J.R. A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes. Biochim. Biophys. Acta 1995, 1239:157-167.
240. Torchilin V.P., Klibanov A.L., Huang L., Odonnell S., Nossiff N.D., Khaw B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 1992, 6:2716-2719.
241. Torchilin V.P., Narula J., Halpern E., Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta 1996, 1279:75-83.
242. Montanari J., Maidana C., Esteva M.I., Salomon C., Morilla M.J., Romero E.L. Sunlight triggered photodynamic ultradeformable liposomes against Leishmania braziliensis are also leishmanicidal in the dark. J. Control. Release 2010, 147:368-376.
243. Love W.G., Duk S., Biolo R., Jori G., Taylor P.W. Liposome-mediated delivery of photosensitizers: localization of zinc(II)-phthalocyanine within implanted tumors after intravenous administration. Photochem. Photobiol. 1996, 63:656-661.
244. Isele U., Schieweck K., Kessler R., Van Hoogevest P., Capraro H.G. Pharmacokinetics and body distribution of liposomal zinc phthalocyanine in tumor-bearing mice-influence of aggregation state, particle-size, and composition. J. Pharm. Sci. 1995, 84:166-173.
245. Visona A., Jori G. Targeting of experimentally-induced atherosclerotic lesions by liposome-delivered Zn(II)-phthalocyanine. Atherosclerosis 1993, 100:213-222.
246. Larroque C., Pelegrin A., Vanlier J.E. Serum albumin as a vehicle for zinc phthalocyanine: photodynamic activities in solid tumour models. Br. J. Cancer 1996, 74:1886-1890.
247. Fadel M., Kassab K., Fadeel D.A. Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice. Lasers Med. Sci. 2010, 25:283-292.
248. Soares M.D., Oliveira M.R., dos Santos E.P., Gitirana L.D., Barbosa G.M., Quaresma C.H., Ricci E. Nanostructured delivery system for zinc phthalocyanine: preparation, characterization, and phototoxicity study against human lung adenocarcinoma A549 cells. Int. J. Nanomed. 2011, 6:227-238.
249. Van Leengoed H.L.L.M., Cuomo V., Versteeg A.A.C., Vanderveen N., Jori G., Star W.M. In vivo fluorescence and photodynamic activity of zinc phthalocyanine administered in liposomes. Br. J. Cancer 1994, 69:840-845.
250. da Silva E.R., de Freitas Z.M.F., Gitirana L.D., Ricci E. Improving the topical delivery of zinc phthalocyanine using oleic acid as a penetration enhancer: in vitro permeation and retention. Drug Dev. Ind. Pharm. 2011, 37:569-575.
251. Lakowicz J.R. Solvent and environmental effects. Principles of Fluorescence Spectroscopy 2006, 205-235. Springer, Baltimore. third ed.
252. Suwa K., Kimura T., Schaap A.P. Reaction of singlet oxygen with cholesterol in liposomal membranes-effect of membrane fluidity on photooxidation of cholesterol. Photochem. Photobiol. 1978, 28:469-473.
253. Stratton S.P., Liebler D.C. Determination of singlet oxygen-specific versus radical-mediated lipid peroxidation in photosensitized oxidation of lipid bilayers: effect of beta-carotene and alpha-tocopherol. Biochemistry 1997, 36:12911-12920.
254. Girotti A.W. Mechanisms of lipid peroxidation. Free Radic. Biol. Med. 1985, 1:87-95.
255. Nunes S.M.T., Sguilla F.S., Tedesco A.C. Photophysical studies of zinc phthalocyanine and chloroaluminum phthalocyanine incorporated into liposomes in the presence of additives. Braz. J. Med. Biol. Res. 2004, 37:273-284.
256. Molinari A., Colone M., Calcabrini A., Stringaro A., Toccacieli L., Arancia G., Mannino S., Mangiola A., Maira G., Bombelli C., Mancini G. Cationic liposomes loaded with m-THPC, in photodynamic therapy for malignant glioma. Toxicol. In Vitro 2007, 21:230-234.
257. Gijsens A., Derycke L., Missiaen D., De Vos J., Huwyler E.A.P. Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int. J. Cancer 2002, 101:78-85.
258. Villanueva A., Stockert J.C., Canete M., Acedo P. A new protocol in photodynamic therapy: enhanced tumour cell death by combining two different photosensitizers. Photochem. Photobiol. Sci. 2010, 9:295-297.
259. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
260. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
261. Koshkaryev A., Sawant R., Deshpande M., Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv. Drug Deliv. Rev. 2013, 65:24-35.
262. Song S.X., Liu D., Peng J.L., Sun Y., Li Z.H., Gu J.R., Xu Y.H. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 2008, 363:155-161.
263. M. Broekgaarden, R. van Vught, T.M. van Gulik, E. Breukink, M. Heger, Development of anti-epidermal growth factor receptor functionalized liposomes with zinc-phthalocyanine for photodynamic therapy. Manuscript in preparation, 2015.
264. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z.X., Hong K.L., Kirpotin D.B., Park J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65:11631-11638.
265. Park J.W., Hong K.L., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8:1172-1181.
266. Nishikawa K., Asai T., Shigematsu H., Shimizu K., Kato H., Asano Y., Takashima S., Mekada E., Oku N., Minamino T. Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer. J. Control. Release 2012, 160:274-280.
267. Garcia-Diaz M., Nonell S., Villanueva A., Stockert J.C., Canete M., Casado A., Mora M., Sagrista M.L. Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity?. Biochim. Biophys. Acta 2011, 1808:1063-1071.
268. Mir Y., Elrington S.A., Hasan T. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomed. Nanotechnol. Biol. Med. 2013, 9:1114-1122.
269. Triesscheijn M., Ruevekamp M., Aalders M., Baas P., Stewart F.A. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response. Photochem. Photobiol. 2005, 81:1161-1167.
270. Fingar V.H., Siegel K.A., Wieman T.J., Doak K.W. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem. Photobiol. 1993, 58:393-399.
271. Cramers P., Ruevekamp M., Oppelaar H., Dalesio O., Baas P., Stewart F.A. Foscan(R) uptake and tissue distribution in relation to photodynamic efficacy. Br. J. Cancer 2003, 88:283-290.
272. Chen B., de Witte P.A. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 2000, 150:111-117.
273. Dolmans D.E.J.G., Kadambi A., Hill J.S., Waters C.A., Robinson B.C., Walker J.P., Fukumura D., Jain R.K. Vascular accumulation of a novel photosensitizer MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res. 2002, 62:2151-2156.
274. Fingar V.H., Kik P.K., Haydon P.S., Cerrito P.B., Tseng M., Abang E., Wieman T.J. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 1999, 79:1702-1708.
275. Heger M., Beek J.F., Moldovan N.I., van der Horst C.M.A.M., van Gemert M.J.C. Towards optimization of selective photothermolysis: prothrombotic pharmaceutical agents as potential adjuvants in laser treatment of port wine stains-a theoretical study. Thromb. Haemost. 2005, 93:242-256.
276. Heger M., van Golen R.F., Broekgaarden M., van den Bos R.R., Neumann H.A.M., van Gulik T.M., van Gemert M.J.C. Endovascular laser-tissue interactions and biological responses in relation to endovenous laser therapy. Lasers Med. Sci. 2014, 29:405-422.
277. Zilberstein J., Schreiber S., Bloemers M.C.W.M., Bendel P., Neeman M., Schechtman E., Kohen F., Scherz A., Salomon Y. Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy. Photochem. Photobiol. 2001, 73:257-266.
278. Madar-Balakirski N., Tempel-Brami C., Kalchenko V., Brenner O., Varon D., Scherz A., Salomon Y. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. Plos One 2010, 5.
279. Zhao G., Rodriguez B.L. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int. J. Nanomed. 2013, 8:61-71.
280. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic lipids activate intracellular signaling pathways. Adv. Drug Deliv. Rev. 2012, 64:1749-1758.
281. Choi W.J., Kim J.K., Choi S.H., Park J.S., Ahn W.S., Kim C.K. Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials 2004, 25:5893-5903.
282. Thurston G., Mclean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., Hanahan D., McDonald D.M. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 1998, 101:1401-1413.
283. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., Torchilin V.P., Munn L.L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002, 62:6831-6836.
284. Diaz S.L., Padler-Karavani V., Ghaderi D., Hurtado-Ziola N., Yu H., Chen X., Brinkman-Van der Linden E.C.M., Varki A., Varki N.M. Sensitive and specific detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PloS One 2009, 4.
285. M. Broekgaarden, R. Weijer, A.I. de Kroon, T.M. van Gulik, M. Heger, Liposomal delivery of Zn(II)-phthalocyanine towards tumor vascular endothelial cells increases efficacy of photodynamic therapy. Manuscript in preparation, 2015.
286. Gross N., Ranjbar M., Evers C., Hua J., Martin G., Schulze B., Michaelis U., Hansen L.L., Agostini H.T. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol. Vision 2013, 19:54-61.
287. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
288. Mueller M.M., Fusenig N.E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
289. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
290. Gomer C.J., Ferrario A., Luna M., Rucker N., Wong S. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment. Lasers Surg. Med. 2006, 38:516-521.
291. Pazos M.D.C., Nader H.B. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz. J. Med. Biol. Res. 2007, 40:1025-1035.
292. van Golen R.F., van Gulik T.M., Heger M. The sterile immune response during hepatic ischemia/reperfusion. Cytokine Growth Factor Rev. 2012, 23:69-84.
293. Amoozgar Z., Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2012, 4:219-233.
294. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv. Drug Deliv. Rev. 1995, 16:141-155.
295. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
296. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 1993, 53:3765-3770.
297. Oku N., Saito N., Namba Y., Tsukada H., Dolphin D., Okada S. Application of long-circulating liposomes to cancer photodynamic therapy. Biol. Pharm. Bull. 1997, 20:670-673.
298. Polo L., Bianco G., Reddi E., Jori G. The effect of different liposomal formulations on the interaction of Zn(II)-phthalocyanine with isolated low and high-density lipoproteins. Int. J. Biochem. Cell Biol. 1995, 27:1249-1255.
299. Decker C., Steiniger F., Fahr A. Transfer of a lipophilic drug (temoporfin) between small unilamellar liposomes and human plasma proteins: influence of membrane composition on vesicle integrity and release characteristics. J. Liposome Res. 2013, 23:154-165.
300. Reshetov V., Zorin V., Siupa A., D'Hallewin M.A., Guillemin F., Bezdetnaya L. Interaction of liposomal formulations of meta-tetra(hydroxyphenyl) chlorin (temoporfin) with serum proteins: protein binding and liposome destruction. Photochem. Photobiol. 2012, 88:1256-1264.
301. Reddi E., Cernuschi S., Biolo R., Jori G. Liposome- or LDL-administered Zn(II)-phthalocyanine as a photodynamic agent for tumours III. Effect of cholesterol on pharmacokinetic and phototherapeutic properties. Lasers Med. Sci. 1990, 5:339-343.
302. Polo L., Valduga G., Jori G., Reddi E. Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int. J. Biochem. Cell Biol. 2002, 34:10-23.
303. Goldstein J.L., Brown M.S. Low-density lipoprotein pathway and its relation to atherosclerosis. Ann. Rev. Biochem. 1977, 46:897-930.
304. Shum P., Kim J.-M., Thompson D.H. Phototriggering of liposomal drug delivery systems. Adv. Drug Deliv. Rev. 2001, 53:273-284.
305. Fomina N., Sankaranarayanan J., Almutairi A. Photochemical mechanisms of light-triggered release from nanocarriers. Adv. Drug Deliv. Rev. 2012, 64:1005-1020.
306. Leung S.J., Romanowski M. Light-activated content release from liposomes. Theranostics 2012, 2:1020-1036.
307. Andreoni A., Cubeddu R., Desilvestri S., Laporta P., Jori G., Reddi E. Hematoporphyrin derivative-experimental evidence for aggregated species. Chem. Phys. Lett. 1982, 88:33-36.
308. Maier A., Tomaselli F., Matzi V., Rehak P., Pinter H., Smolle-Juttner F.M. Photosensitization with hematoporphyrin derivative compared to 5-aminolaevulinic acid for photodynamic therapy of esophageal carcinoma. Ann. Thorac. Surg. 2001, 72:1136-1140.
309. Zimcik P., Miletin M. Photodynamic therapy. Dyes and Pigments: New Reserach 2009, 1-62. Nova Science Publishers Inc., New York. A.R. Lang (Ed.).
310. Oertel M., Schastak S.I., Tannapfel A., Hermann R., Sack U., Mossner J., Berr F. Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. J. Photochem. Photobiol. B 2003, 71:1-10.
311. Pereira S.P., Ayaru L., Ackroyd R., Mitton D., Fullarton G., Zammit M., Grzebieniak Z., Messmann H., Ortner M.A., Gao L., Trinh M.M., Spenard J. The pharmacokinetics and safety of porfimer after repeated administration 30-45 days apart to patients undergoing photodynamic therapy. Aliment. Pharmacol. Ther. 2010, 32:821-827.
312. Dougherty T.J., Cooper M.T., Mang T.S. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg. Med. 1990, 10:485-488.
313. Woods J.A., Traynor N.J., Brancaleon L., Moseley H. The effect of Photofrin on DNA strand breaks and base oxidation in HaCaT keratinocytes: a comet assay study. Photochem. Photobiol. 2004, 79:105-113.
314. Dalton J.T., Yates C.R., Yin D.H., Straughn A., Marcus S.L., Golub A.L., Meyer M.C. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J. Pharmacol. Exp. Ther. 2002, 301:507-512.
315. Webber J., Kessel D., Fromm D. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J. Photochem. Photobiol. B 1997, 37:151-153.
316. Ackermann G., Abels C., Baumler W., Langer S., Landthaler M., Lang E.W., Szeimies R.M. Simulations on the selectivity of 5-aminolaevulinic acid-induced fluorescence in vivo. J. Photochem. Photobiol. B 1998, 47:121-128.
317. Ris H.B., Altermatt H.J., Inderbitzi R., Hess R., Nachbur B., Stewart J.C.M., Wang Q., Lim C.K., Bonnett R., Berenbaum M.C., Althaus U. Photodynamic therapy with chlorins for diffuse malignant mesothelioma-initial clinical results. Br. J. Cancer 1991, 64:1116-1120.
318. Ricci-Junior E., Marchetti J.M. Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. Int. J. Pharm. 2006, 310:187-195.
319. Chen Z., Zhou S.Y., Chen J.C., Deng Y.C., Luo Z.P., Chen H.W., Hamblin M.R., Huang M.D. Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy. Chem. Med. Chem. 2010, 5:890-898.
320. Taillefer J., Jones M.C., Brasseur N., van Lier J.E., Leroux J.C. Preparation and characterization of pH-responsive polymeric micelles for the delivery of photosensitizing anticancer drugs. J. Pharm. Sci. 2000, 89:52-62.
321. Fang Y.P., Wu P.C., Tsai Y.H., Huang Y.B. Physicochemical and safety evaluation of 5-aminolevulinic acid in novel liposomes as carrier for skin delivery. J. Liposome Res. 2008, 18:31-45.
322. Sadzuka Y., Tokutomi K., Iwasaki F., Sugiyama I., Hirano T., Konno H., Oku N., Sonobe T. The phototoxicity of Photofrin was enhanced by PEGylated liposome in vitro. Cancer Lett. 2006, 241:42-48.
323. Soriano J., Garcia-Diaz M., Mora M., Sagrista M.L., Nonell S., Villanueva A., Stockert J.C., Canete M. Liposomal temocene (m-THPPo) photodynamic treatment induces cell death by mitochondria-independent apoptosis. Biochim. Biophys. Acta 2013, 1830:4611-4620.
324. Sharma G., Anabousi S., Ehrhardt C., Ravi Kumar M.N.V. Liposomes as targeted drug delivery systems in the treatment of breast cancer. J. Drug Target. 2006, 14:301-310.
325. Marotta D.E., Cao W., Wileyto E.P., Li H., Corbin I., Rickter E., Glickson J.D., Chance B., Zheng G., Busch T.M. Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo. Nanomedicine (London England) 2011, 6:475-487.
326. Li H., Marotta D.E., Kim S., Busch T.M., Wileyto E.P., Zheng G. High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. J. Biomed. Opt. 2005, 10:41203.
327. Decreau R., Richard M.J., Verrando P., Chanon M., Julliard M. Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes. J. Photochem. Photobiol. B 1999, 48:48-56.
328. Garcia-Diaz M., Kawakubo M., Mroz P., Sagrista M.L., Mora M., Nonell S., Hamblin M.R. Cellular and vascular effects of the photodynamic agent temocene are modulated by the delivery vehicle. J. Control. Release 2012, 162:355-363.
329. Shao J., Dai Y., Zhao W., Xie J., Xue J., Ye J., Jia L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc(II)-phthalocyanine solubilized in Cremophor EL against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 2013, 330:49-56.
330. Bagwe R.P., Kanicky J.R., Palla B.J., Patanjali P.K., Shah D.O. Improved drug delivery using microemulsions: rationale, recent progress, and new horizons. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18:77-140.
331. Lima A.M., Pizzol C.D., Monteiro F.B., Creczynski-Pasa T.B., Andrade G.P., Ribeiro A.O., Perussi J.R. Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency. J. Photochem. Photobiol. B 2013, 125:146-154.
332. Navarro F.P., Creusat G., Frochot C., Moussaron A., Verhille M., Vanderesse R., Thomann J.S., Boisseau P., Texier I., Couffin A.C., Barberi-Heyob M. Preparation and characterization of mTHPC-loaded solid lipid nanoparticles for photodynamic therapy. J. Photochem. Photobiol. B 2014, 130:161-169.
333. Pardeshi C., Rajput P., Belgamwar V., Tekade A., Patil G., Chaudhary K., Sonje A. Solid lipid based nanocarriers: an overview. Acta Pharm. (Zagreb, Croatia) 2012, 62:433-472.
334. Battah S.H., Chee C.E., Nakanishi H., Gerscher S., MacRobert A.J., Edwards C. Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjugate Chem. 2001, 12:980-988.
335. Taratula O., Schumann C., Naleway M.A., Pang A.J., Chon K.J., Taratula O. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Mol. Pharm. 2013, 10:3946-3958.
336. Mohammadi Z., Sazgarnia A., Rajabi O., Soudmand S., Esmaily H., Sadeghi H.R. An in vitro study on the photosensitivity of 5-aminolevulinic acid conjugated gold nanoparticles. Photodiagn. Photodyn. Ther. 2013, 10:382-388.
337. Eshghi H., Sazgarnia A., Rahimizadeh M., Attaran N., Bakavoli M., Soudmand S. Protoporphyrin IX-gold nanoparticle conjugates as an efficient photosensitizer in cervical cancer therapy. Photodiagn. Photodyn. Ther. 2013, 10:304-312.
338. Stuchinskaya T., Moreno M., Cook M.J., Edwards D.R., Russell D.A. Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates. Photochem. Photobiol. Sci. 2011, 10:822-831.
339. Arvizo R., Bhattacharya R., Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv. 2010, 7:753-763.
340. Hofman J.W., Carstens M.G., van Zeeland F., Helwig C., Flesch F.M., Hennink W.E., van Nostrum C.F. Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation. Pharm. Res. 2008, 25:2065-2073.
341. Master A.M., Rodriguez M.E., Kenney M.E., Oleinick N.L., Gupta A.S. Delivery of the photosensitizer Pc 4 in PEG-PCL micelles for in vitro PDT studies. J Pharm Sci. 2010, 99:2386-2398.
342. Lamch L., Bazylinska U., Kulbacka J., Pietkiewicz J., Biezunska-Kusiak K., Wilk K.A. Polymeric micelles for enhanced Photofrin II (R) delivery, cytotoxicity and pro-apoptotic activity in human breast and ovarian cancer cells. Photodiagn. Photodyn. Ther. 2014, 11:570-585.
343. Sibata M.N., Tedesco A.C., Marchetti J.M. Photophysicals and photochemicals studies of zinc(II) phthalocyanine in long time circulation micelles for photodynamic therapy use. Eur. J. Pharm. Sci. 2004, 23:131-138.
344. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin. Drug Deliv. 2010, 7:145-158.
345. Shi L., Wang X., Zhao F., Luan H., Tu Q., Huang Z., Wang H., Wang H. In vitro evaluation of 5-aminolevulinic acid (ALA) loaded PLGA nanoparticles. Int. J. Nanomed. 2013, 8:2669-2676.
346. Vaidya A., Sun Y., Feng Y., Emerson L., Jeong E.K., Lu Z.R. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm. Res. 2008, 25:2002-2011.
347. Martynenko I.V., Kuznetsova V.A., Orlova A.O., Kanaev P.A., Maslov V.G., Loudon A., Zaharov V., Parfenov P., Gun'ko Y.K., Baranov A.V., Fedorov A.V. Chlorin e6-ZnSe/ZnS quantum dots based system as reagent for photodynamic therapy. Nanotechnology 2015, 26:55102.
348. Fowley C., Nomikou N., McHale A.P., McCaughan B., Callan J.F. Extending the tissue penetration capability of conventional photosensitisers: a carbon quantum dot-protoporphyrin IX conjugate for use in two-photon excited photodynamic therapy. Chem. Commun. (Cambridge, England) 2013, 49:8934-8936.
349. Tsay J.M., Trzoss M., Shi L., Kong X., Selke M., Jung M.E., Weiss S. Singlet oxygen production by peptide-coated quantum dot-photosensitizer conjugates. J. Am. Chem. Soc. 2007, 129:6865-6871.
350. Drbohlavova J., Adam V., Kizek R., Hubalek J. Quantum dots-characterization, preparation and usage in biological systems. Int. J. Mol. Sci. 2009, 10:656-673.
351. Sapra P., Allen T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002, 62:7190-7194.
352. Sapra P., Moase E.H., Ma J., Allen T.M. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin. Cancer Res. 2004, 10:1100-1111.
353. Mamot C., Ritschard R., Kung W., Park J.W., Herrmann R., Rochlitz C.F. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Target. 2006, 14:215-223.
354. Kim I.Y., Kang Y.S., Lee D.S., Park H.J., Choi E.K., Oh Y.K., Son H.J., Kim J.S. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release 2009, 140:55-60.
355. Mortensen J.H., Jeppesen M., Pilgaard L., Agger R., Duroux M., Zachar V., Moos T. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme. J. Drug Deliv. 2013, 2013:209205.
356. Lehtinen J., Raki M., Bergstrom K.A., Uutela P., Lehtinen K., Hiltunen A., Pikkarainen J., Liang H.M., Pitkanen S., Maatta A.M., Ketola R.A., Yliperttula M., Wirth T., Urtti A. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. Plos One 2012, 7. e41410.
357. Pastorino F., Brignole C., Marimpietri D., Sapra P., Moase E.H., Allen T.M., Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003, 63:86-92.
358. Nielsen U.B., Kirpotin D.B., Pickering E.M., Hong K.L., Park J.W., Shalaby M.R., Shao Y., Benz C.C., Marks J.D. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta. 2002, 1591:109-118.
359. Gao J., Zhong W., He J.Q., Li H.M., Zhang H., Zhou G.C., Li B.H., Lu Y., Zou H., Kou G., Zhang D.P., Wang H., Guo Y.J., Zhong Y.Q. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm. 2009, 374:145-152.
360. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.L., Carter P., Benz C.C., Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997, 36:66-75.
361. Hantel C., Lewrick F., Schneider S., Zwermann O., Perren A., Reincke M., Suss R., Beuschlein F. Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency. J. Clin. Endocrinol. Metab. 2010, 95:943-952.
362. Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., Yasuda J., Obata K., Kikuchi H., Ishida T., Kiwada H., Harashima H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm. 2007, 342:194-200.
363. Gosk S., Moos T., Gottstein C., Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim. Biophys. Acta 2008, 1778:854-863.
364. Roth P., Hammer C., Piguet A.C., Ledermann M., Dufour J.F., Waelti E. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2. J. Drug Target. 2007, 15:623-631.
365. Wicki A., Rochlitz C., Orleth A., Ritschard R., Albrecht I., Herrmann R., Christofori G., Mamot C. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin. Cancer Res. 2012, 18:454-464.
366. Lipponen P., Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer 1994, 69:1120-1125.
367. Turkeri L.N., Erton M.L., Cevik I., Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 1998, 51:645-649.
368. Olsson H., Fyhr I.M., Hultman P., Jahnson S. HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand. J. Urol. Nephrol. 2012, 46:102-107.
369. Abd Elazeez T.A., El-Balshy A., Khalil M.M., El-Tabye M.M., Abdul-Halim H. Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. Urol. Ann. 2011, 1:8-13.
370. Cao X.J., Hao J.F., Yang X.H., Xie P., Liu L.P., Yao C.P., Xu J. Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma. Med. Oncol. 2012, 29:263-271.
371. Kim T.J., Lee Y.S., Kang J.H., Kim Y.S., Kang C.S. Prognostic significance of expression of VEGF and Cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. J. Surg. Oncol. 2011, 103:46-52.
372. Pan J.J., Kong L., Lin S.N., Chen G., Chen Q., Lu J.J. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008, 118:1970-1975.
373. Soo R., Putti T., Tao Q., Goh B.C., Lee K.H., Kwok-Seng L., Tan L., Hsieh W.S. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. Arch. Otolaryngol. Head Neck Surg. 2005, 131:147-152.
374. Yuan Y.L., Zhou X.H., Song J., Qiu X.P., Li J., Ye L.F., Meng X.P., Xia D. Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann. Otol. Rhinol. Laryngol. 2008, 117:192-200.
375. Harder J., Waiz O., Otto F., Geissler M., Olschewski M., Weinhold B., Blum H.E., Schmitt-Graeff A., Opitz O.G. EGFR and HER2 expression in advanced biliary tract cancer. World J. Gastroenterol. 2009, 15:4511-4517.
376. Pignochino Y., Sarotto I., Peraldo-Neia C., Penachioni J.Y., Cavalloni G., Migliardi G., Casorzo L., Chiorino G., Risio M., Bardelli A., Aglietta M., Leone F. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010, 10:631.
377. Wiedmann M., Feisthammel J., Bluthner T., Tannapfel A., Kamenz T., Kluge A., Mossner J., Caca K. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006, 17:783-795.
378. Yoshikawa D., Ojima H., Iwasaki M., Hiraoka N., Kosuge T., Kasai S., Hirohashi S., Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br. J. Cancer 2008, 98:418-425.
379. Kawamoto T., Krishnamurthy S., Tarco E., Trivedi S., Wistuba I.I., Li D., Roa I., Roa J.C., Thomas M.B. HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest. Cancer Res. 2007, 6:221-227.
380. Kim H.J., Yoo T.W., Park D.I., Park J.H., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Kim M.K., Chae S.W., Sohn J.H. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann. Oncol. 2007, 18:892-897.
381. Zheng J., Zhu Y.M. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat. Dis. Int. 2007, 6:412-415.
382. VCCLAB, Virtual Computational Chemistry Laboratory, 2005. http://www.vcclab.org.
383. S. Jacques, Optical absorption of melanin, Oregon Medical Laser Center, 2012. http://omlc.ogi.edu/spectra/melanin/.
384. S. Prahl, Optical absorption of hemoglobin, Oregon Medical Laser Center, 2012. http://omlc.ogi.edu/spectra/hemoglobin/.
385. Kang R., Livesey K.M., Zeh H.J., Lotze M.T., Tang D.L. HMGB1 A novel Beclin 1-binding protein active in autophagy. Autophagy 2010, 6:1209-1211.
386. Kloek J.J., Marechal X., Roelofsen J., Houtkooper R.H., van Kuilenburg A.B.P., Kulik W., Bezemer R., Neviere R., van Gulik T.M., Heger M. Cholestasis is associated with hepatic microvascular dysfunction and aberrant energy metabolism before and during ischemia-reperfusion. Antioxid. Redox Signaling 2012, 17:1109-1123.
387. Post I.C.J.H., de Boon W.M.I., Heger M., van Wijk A.C.W.A., Kroon J., van Buul J.D., van Gulik T.M. Endothelial cell preservation at hypothermic to normothermic conditions using clinical and experimental organ preservation solutions. Exp. Cell Res. 2013, 319:2501-2513.